MX9708959A - PROCESO NOVEDOSO PARA LA PRODUCCION DE SAL DE CALCIO DE ACIDO [R-(R*R*)]-2-(4-FLUOROFENIL)- beta,&-DIHIDROXI-5-(1-METILETIL)-3 -FENIL-4-[(FENILAMINO)CARBONIL)-1H-PIRROLE-1-HEPTANOICO AMORFO (2:1). - Google Patents

PROCESO NOVEDOSO PARA LA PRODUCCION DE SAL DE CALCIO DE ACIDO [R-(R*R*)]-2-(4-FLUOROFENIL)- beta,&-DIHIDROXI-5-(1-METILETIL)-3 -FENIL-4-[(FENILAMINO)CARBONIL)-1H-PIRROLE-1-HEPTANOICO AMORFO (2:1).

Info

Publication number
MX9708959A
MX9708959A MX9708959A MX9708959A MX9708959A MX 9708959 A MX9708959 A MX 9708959A MX 9708959 A MX9708959 A MX 9708959A MX 9708959 A MX9708959 A MX 9708959A MX 9708959 A MX9708959 A MX 9708959A
Authority
MX
Mexico
Prior art keywords
amorphous
phenylamino
methylethyl
fluorophenyl
pyrrole
Prior art date
Application number
MX9708959A
Other languages
English (en)
Spanish (es)
Inventor
Dieter Schweiss
Min Lin
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21696097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9708959(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MX9708959A publication Critical patent/MX9708959A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
MX9708959A 1995-07-17 1996-07-16 PROCESO NOVEDOSO PARA LA PRODUCCION DE SAL DE CALCIO DE ACIDO [R-(R*R*)]-2-(4-FLUOROFENIL)- beta,&-DIHIDROXI-5-(1-METILETIL)-3 -FENIL-4-[(FENILAMINO)CARBONIL)-1H-PIRROLE-1-HEPTANOICO AMORFO (2:1). MX9708959A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US145395P 1995-07-17 1995-07-17
PCT/US1996/011807 WO1997003960A1 (en) 1995-07-17 1996-07-16 NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1)

Publications (1)

Publication Number Publication Date
MX9708959A true MX9708959A (es) 1998-03-31

Family

ID=21696097

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9708959A MX9708959A (es) 1995-07-17 1996-07-16 PROCESO NOVEDOSO PARA LA PRODUCCION DE SAL DE CALCIO DE ACIDO [R-(R*R*)]-2-(4-FLUOROFENIL)- beta,&-DIHIDROXI-5-(1-METILETIL)-3 -FENIL-4-[(FENILAMINO)CARBONIL)-1H-PIRROLE-1-HEPTANOICO AMORFO (2:1).

Country Status (37)

Country Link
US (1) US6274740B1 (member.php)
EP (1) EP0839132B1 (member.php)
JP (1) JP4064459B2 (member.php)
KR (1) KR100400805B1 (member.php)
CN (1) CN1087289C (member.php)
AR (1) AR002849A1 (member.php)
AT (1) ATE199542T1 (member.php)
AU (1) AU700794B2 (member.php)
BG (1) BG63631B1 (member.php)
BR (1) BR9609714A (member.php)
CA (1) CA2220455C (member.php)
CO (1) CO4700441A1 (member.php)
CZ (1) CZ289421B6 (member.php)
DE (1) DE69611999T2 (member.php)
DK (1) DK0839132T5 (member.php)
EA (1) EA000625B1 (member.php)
EE (1) EE03605B1 (member.php)
ES (1) ES2156997T3 (member.php)
GE (1) GEP20002027B (member.php)
GR (1) GR3035859T3 (member.php)
HR (1) HRP960312B1 (member.php)
HU (1) HU220343B (member.php)
IL (1) IL122161A (member.php)
IN (1) IN185276B (member.php)
MX (1) MX9708959A (member.php)
NO (1) NO309322B1 (member.php)
NZ (1) NZ313008A (member.php)
PE (1) PE1698A1 (member.php)
PL (1) PL191017B1 (member.php)
PT (1) PT839132E (member.php)
RO (1) RO120069B1 (member.php)
SI (1) SI0839132T1 (member.php)
SK (1) SK283204B6 (member.php)
UA (1) UA50743C2 (member.php)
UY (1) UY24286A1 (member.php)
WO (1) WO1997003960A1 (member.php)
ZA (1) ZA966043B (member.php)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
IN191236B (member.php) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
HU226640B1 (en) * 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
US6646133B1 (en) 2000-10-17 2003-11-11 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
SK7212003A3 (en) * 2000-11-16 2004-03-02 Teva Pharma Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy- 5-(1-methylethyl)-3-fenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1- heptanoic acid esters with calcium hydroxide
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622477A1 (en) 2000-12-27 2002-07-04 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
WO2002057228A1 (en) * 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (member.php) * 2001-04-11 2003-08-09 Cadila Heathcare Ltd
IL158790A0 (en) 2001-06-29 2004-05-12 Warner Lambert Co Crystalline forms of [r-(*,r*)]-2-(4-fluorophenyl) -beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
US7361772B2 (en) 2001-08-16 2008-04-22 Biocon Limited Process for the production of atorvastatin calcium
AU2001284385A1 (en) 2001-08-31 2003-03-10 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs) 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
RU2309141C2 (ru) * 2002-03-18 2007-10-27 Байокон Лимитид АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
HUP0500074A3 (en) 2002-03-18 2005-07-28 Biocon Ltd Bangalore Amorphous hmg-coa reductase inhibitors of desired particle size and process for producing them
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
WO2003099785A1 (en) * 2002-05-28 2003-12-04 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
US7179942B2 (en) 2002-07-05 2007-02-20 Bicon Limited Halo-substituted active methylene compounds
AU2002330735A1 (en) * 2002-09-03 2004-03-29 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
CA2520740C (en) 2003-04-11 2012-06-05 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
EP1631533B1 (en) 2003-04-22 2009-03-11 Biocon Limited Novel process for stereoselective reduction of beta-ketoesters
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7557238B2 (en) 2003-09-18 2009-07-07 Biocon Limited Process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
CZ298382B6 (cs) * 2004-03-10 2007-09-12 Zentiva, A. S. Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace
AU2004317570B2 (en) 2004-03-17 2011-01-06 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
EP2540704B1 (en) * 2004-05-05 2019-07-03 Pfizer Products Inc. Benethamine salt forms of atorvastatin
EP1771455B1 (en) * 2004-07-16 2016-05-11 LEK Pharmaceuticals d.d. Oxidative degradation products of atorvastatin calcium
WO2006021969A1 (en) 2004-08-27 2006-03-02 Biocon Limited Process for atorvastatin calcium amorphous
EP1793815A4 (en) * 2004-09-30 2010-12-29 Reddys Lab Ltd Dr AMORPHES ATORVASTATINCALCIUM
MX2007004425A (es) * 2004-10-18 2007-06-07 Teva Pharma Proceso para preparar hemi-calcio de atorvastatina amorfo disolviendo la sal en un solvente organico que es una mezcla de un alcohol y una cetona y/o un ester y removiendo el solvente.
EP1807055A1 (en) * 2004-10-28 2007-07-18 Warner-Lambert Company LLC Process for forming amorphous atorvastatin
WO2006054308A2 (en) 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
EP1819319A1 (en) * 2004-12-02 2007-08-22 Warner-Lambert Company LLC Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
US20070249845A1 (en) * 2006-03-01 2007-10-25 Michael Pinchasov Process for preparing a crystalline form of atorvastatin hemi-calcium
US20100113802A1 (en) * 2006-11-02 2010-05-06 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
US20100260851A1 (en) * 2007-07-11 2010-10-14 Actavis Group Ptc Ehf Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium
US20090124817A1 (en) * 2007-11-09 2009-05-14 The Industry & Academic Cooperation In Chungnam National University Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
WO2010066846A2 (en) * 2008-12-11 2010-06-17 Dsm Ip Assets B.V. Method for the isolation of atorvastatin
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
SI2373609T1 (sl) 2008-12-19 2013-12-31 Krka, D.D., Novo Mesto Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
IL128864A (en) 1995-07-17 2007-10-31 Warner Lambert Co Atorostatin II form crystals and its hydrates, methods of preparation and pharmaceutical preparations containing it

Also Published As

Publication number Publication date
UY24286A1 (es) 1997-01-17
NZ313008A (en) 2000-01-28
CO4700441A1 (es) 1998-12-29
BG63631B1 (bg) 2002-07-31
ES2156997T3 (es) 2001-08-01
SI0839132T1 (member.php) 2001-06-30
AU6497896A (en) 1997-02-18
SK5898A3 (en) 1998-08-05
UA50743C2 (uk) 2002-11-15
JPH11510486A (ja) 1999-09-14
NO309322B1 (no) 2001-01-15
HRP960312A2 (en) 1998-02-28
CA2220455C (en) 2002-09-24
GEP20002027B (en) 2000-04-10
EE9700369A (et) 1998-06-15
PL324463A1 (en) 1998-05-25
US6274740B1 (en) 2001-08-14
NO980209L (no) 1998-01-16
HK1018054A1 (en) 1999-12-10
ATE199542T1 (de) 2001-03-15
AU700794B2 (en) 1999-01-14
EP0839132A1 (en) 1998-05-06
IN185276B (member.php) 2000-12-16
DE69611999D1 (de) 2001-04-12
PL191017B1 (pl) 2006-03-31
EA199800128A1 (ru) 1998-08-27
HU220343B (hu) 2001-12-28
EA000625B1 (ru) 1999-12-29
IL122161A (en) 1999-07-14
ZA966043B (en) 1997-02-03
HRP960312B1 (en) 2001-10-31
DK0839132T5 (da) 2006-03-20
PT839132E (pt) 2001-06-29
DE69611999T2 (de) 2001-07-26
CN1190956A (zh) 1998-08-19
IL122161A0 (en) 1998-04-05
KR100400805B1 (ko) 2003-12-24
BG102188A (en) 1998-08-31
AR002849A1 (es) 1998-04-29
JP4064459B2 (ja) 2008-03-19
EP0839132B1 (en) 2001-03-07
GR3035859T3 (en) 2001-08-31
PE1698A1 (es) 1998-02-19
WO1997003960A1 (en) 1997-02-06
NO980209D0 (no) 1998-01-16
RO120069B1 (ro) 2005-08-30
HUP9903017A3 (en) 2001-01-29
SK283204B6 (sk) 2003-03-04
EE03605B1 (et) 2002-02-15
CN1087289C (zh) 2002-07-10
CA2220455A1 (en) 1997-02-06
CZ289421B6 (cs) 2002-01-16
KR19990029045A (ko) 1999-04-15
CZ12298A3 (cs) 1998-12-16
BR9609714A (pt) 1999-02-23
DK0839132T3 (da) 2001-04-09

Similar Documents

Publication Publication Date Title
MX9708959A (es) PROCESO NOVEDOSO PARA LA PRODUCCION DE SAL DE CALCIO DE ACIDO [R-(R*R*)]-2-(4-FLUOROFENIL)- beta,&-DIHIDROXI-5-(1-METILETIL)-3 -FENIL-4-[(FENILAMINO)CARBONIL)-1H-PIRROLE-1-HEPTANOICO AMORFO (2:1).
PL324496A1 (en) Crystalline fsemi-calcinous salt of [r-(r*,r*)]-2-(4-fluorophenyl)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrolo-1-enantanic acid (atorvastatin)
BG102186A (en) Crystalline form iii of hemicalcium salts of [r-(r*, r*)]-2-(4-fluorophenyl)-beta,delta -dyhydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h -ppyrol-1-heptane acid (atorvastatin)
YU36802A (sh) Postupak za dobijanje amorfnog atorvastatina
NZ507836A (en) Crystalline [r*(r* ,r*)]-2-(4-flurophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)